+63.3%
CVX vs MRNA
+153.9%
-90.6%
-20.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.9% | -2.2% | +3.1% | +0.9% |
| 7D | -4.5% | -12.7% | +8.2% | -4.4% |
| 30D | -7.4% | -20.7% | +13.3% | -7.3% |
| 3M | +2.1% | +46.3% | -44.2% | +1.8% |
| 6M | +10.8% | +305.2% | -294.5% | +8.4% |
| YTD | +41.7% | +561.2% | -519.5% | +34.4% |
| 1Y | +43.7% | +772.1% | -728.4% | +34.0% |
| 3Y | +63.3% | +147.0% | -83.7% | +50.5% |
| All | +63.3% | +153.9% | -90.6% | +50.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling